Brain Imaging Biomarkers in Patients With Brain Metastasis
ConditionBrain Metastases, Adult
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity Health Network, Toronto
About this trial
A biomarker is a measurable indicator of the severity or presence of some disease state. In this study, brain metastases patients who will be receiving radiation treatment, will undergo CT (Computed Tomography) and MRI (Magnetic Resonance Imaging) scans prior to and after radiation treatment to measure these biomarkers. This is a single-center phase II study to validate the predictive abilities of biomarkers, in terms of determining how patients will respond to radiation treatment.
Eligibility criteria
Qualifiers
Biopsy proven primary malignancy (original biopsy is adequate as long as the brain imaging is consistent with brain metastases)
At least one index lesion with diameter > 1cm and without imaging evidence of hemorrhage
Patients age > 18 years of age
Patients planned for RT to brain metastases
Disqualifiers
Previous Whole Brain Radiotherapy
Previous radiosurgery to the index lesion
Individuals unable to undergo contrasted MRI for whatever reason
Trial design
Treatments tested in this trial
- CT and MRI Scans
Treatment groups
90 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov